Form 4: CFO Timothy Dec's RSU Vesting & Tax Withholding

Supernus Pharmaceuticals CFO Timothy Dec reported the vesting of 2,500 restricted stock units and a subsequent sale of shares for tax purposes.

Summary

• Timothy C. Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on February 25, 2026.
• 2,500 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 2,500 shares of common stock at a price of $0.
• Concurrently, 1,279 shares of common stock were disposed of (sold) by the company to satisfy tax withholding requirements related to the RSU vesting, at a price of $50.69 per share.
• Following these transactions, Timothy C. Dec directly beneficially owns 5,115 shares of common stock.
• Additionally, 2,500 Restricted Stock Units remain beneficially owned, which are part of a grant that vests in four equal annual installments, with the first installment beginning on February 23, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, with no significant positive or negative implications for the company's fundamentals or immediate stock price.

Positives

• The vesting of Restricted Stock Units indicates the execution of a pre-established long-term incentive compensation plan for a key executive.

Negatives

• A portion of the vested shares (1,279 shares) was sold to cover tax obligations, resulting in a reduction of direct share ownership.

Future Outlook

The remaining 2,500 Restricted Stock Units are expected to vest in future installments as part of the four equal annual vesting schedule that began on February 23, 2024.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are a standard component of executive compensation packages across various industries, designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The structure of RSU grants with multi-year vesting schedules and tax withholding at vesting is a common practice for executive compensation in the pharmaceutical and biotechnology sectors, comparable to practices at companies like Biogen or Gilead Sciences.

Stakeholder Impact

• Shareholders: The transaction represents a minor, pre-planned change in insider ownership, which is generally not considered to have a significant impact.
• Employees: No direct impact on the broader employee base.

Next Steps

• Future vesting installments of the remaining 2,500 Restricted Stock Units.

Key Dates

Recommendation

This Form 4 reports a routine vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, which is a common occurrence for executive compensation. It does not provide new fundamental information to alter an investment thesis or warrant a change in recommendation.

Keywords

Supernus Pharmaceuticals, SUPN, Timothy C. Dec, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, CFO